Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine
Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine -- Results found that patients treated with Evrysdi at 12 months demonstrated significant improvements in survival and developmental milestones -- -- The U.S. Food and Drug Administration approved Evrysdi in August 2020 as the first and only at home SMA treatment with proven efficacy in adults, children and infants 2 months and older -- News provided by Share this article Share this article SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire...
Source: prnewswire.com